Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics

International Journal of Cancer

Volumn 131, Issue 1, 2012, Pages 30-40

  Tang, Su Ni ^a   Fu, Junsheng ^a   Nall, Dara ^a   Rodova, Mariana ^a   Shankar, Sharmila ^a   Srivastava, Rakesh K ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

cancer stem cells; EGCG; epithelial mesenchymal transition; pancreatic cancer; pluripotency maintaining factors; RNAi; sonic hedgehog pathway

Indexed keywords

CASPASE 3; CASPASE 7; EPIGALLOCATECHIN GALLATE; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN BCL 2; QUERCETIN; SHORT HAIRPIN RNA; SONIC HEDGEHOG PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR NANOG; X LINKED INHIBITOR OF APOPTOSIS;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SPHEROID;

APOPTOSIS; CASPASE 3; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; EPITHELIAL-MESENCHYMAL TRANSITION; HEDGEHOG PROTEINS; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PANCREATIC NEOPLASMS; PLANT EXTRACTS; PLURIPOTENT STEM CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; QUERCETIN; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TEA; TRANSCRIPTION, GENETIC; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84860214416     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26323     Document Type: Article

References (45)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Pliarchopoulou K, Pectasides D,. Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev 2009; 35: 431-6.
3. Magee CJ, Ghaneh P, Neoptolemos JP,. Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol 2002; 16: 435-55.
4. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, Abrams RA, Laheru D, et al. Pancreatic cancer. Curr Probl Cancer 2002; 26: 176-275.
5. Warshaw AL, Fernandez-del Castillo C,. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65.
6. Jones RJ, Matsui WH, Smith BD,. Cancer stem cells: are we missing the target?. J Natl Cancer Inst 2004; 96: 583-5.
7. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
8. Ischenko I, Seeliger H, Kleespies A, Angele MK, Eichhorn ME, Jauch KW, Bruns CJ,. Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg 2010; 395: 1-10.
9. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, Srivastava RK,. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 2011; 6: e16530.
10. Jones RJ,. Cancer stem cells: clinical relevance. J Mol Med 2009; 87: 1105-10.
11. Varjosalo M, Taipale J,. Hedgehog: functions and mechanisms. Genes Dev 2008; 22: 2454-72.
12. Beachy PA, Karhadkar SS, Berman DM,. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004; 432: 324-31.
13. Rohatgi R, Scott MP,. Patching the gaps in Hedgehog signalling. Nat Cell Biol 2007; 9: 1005-9.
14. Osterlund T, Kogerman P,. Hedgehog signalling: how to get from Smo to Ci and Gli. Trends Cell Biol 2006; 16: 176-80.
15. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-61.
16. Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, Beaty R, Mullendore M, Karikari C, Bardeesy N, Ouellette MM, Yu W, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008; 57: 1420-30.
17. Lee CJ, Dosch J, Simeone DM,. Pancreatic cancer stem cells. J Clin Oncol 2008; 26: 2806-12.
18. Ishizawa K, Izawa-Ishizawa Y, Ohnishi S, Motobayashi Y, Kawazoe K, Hamano S, Tsuchiya K, Tomita S, Minakuchi K, Tamaki T,. Quercetin glucuronide inhibits cell migration and proliferation by platelet-derived growth factor in vascular smooth muscle cells. J Pharmacol Sci 2009; 109: 257-64.
19. Nair HB, Sung B, Yadav VR, Kannappan R, Chaturvedi MM, Aggarwal BB,. Delivery of anti-inflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem Pharmacol 2010; 80: 1833-43.
20. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A,. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007; 6: 2591-9.
21. Zhang L, Angst E, Park JL, Moro A, Dawson DW, Reber HA, Eibl G, Hines OJ, Go VL, Lu QY,. Quercetin aglycone is bioavailable in murine pancreas and pancreatic xenografts. J Agric Food Chem 2010; 58: 7252-7.
22. Duraj J, Zazrivcova K, Bodo J, Sulikova M, Sedlak J,. Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma 2005; 52: 273-9.
23. Knekt P, Jarvinen R, Seppanen R, Hellovaara M, Teppo L, Pukkala E, Aromaa A,. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol 1997; 146: 223-30.
24. Mi Y, Zhang C, Li C, Taneda S, Watanabe G, Suzuki AK, Taya K,. Quercetin attenuates oxidative damage induced by treatment of embryonic chicken spermatogonial cells with 4-nitro-3-phenylphenol in diesel exhaust particles. Biosci Biotechnol Biochem 2010; 74: 934-8.
25. Srivastava RK, Tang SN, Zhu W, Meeker D, Shankar S,. Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells. Front Biosci (Elite Ed) 2011; 3: 515-28.
26. Tang SN, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK,. The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 2010; 5: 14.
27. Srivastava RK,. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001; 3: 535-46.
28. Cavaleri F, Scholer HR,. Nanog: a new recruit to the embryonic stem cell orchestra. Cell 2003; 113: 551-2.
29. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, Gudas LJ, Mongan NP,. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG. OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell micro. RNAs. Stem Cells Dev 2009; 18: 1093-108.
30. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ, Tang DG,. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009; 27: 993-1005.
31. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S,. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003; 113: 631-42.
32. Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT, Kelley V, Jorgensen M, Steindler DA, Vieweg J, Siemann DW,. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010; 183: 2045-53.
33. Thiery JP, Acloque H, Huang RY, Nieto MA,. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
34. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M,. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010; 101: 293-9.
35. Mueller MT, Hermann PC, Heeschen C,. Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci (Elite Ed) 2010; 2: 602-13.
36. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, Sarkar FH,. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011; 8: 27-33.
37. Maitra A, Hruban RH,. Pancreatic cancer. Annu Rev Pathol 2008; 3: 157-88.
38. Dai J, Ai K, Du Y, Chen G,. Sonic hedgehog expression correlates with distant metastasis in pancreatic adenocarcinoma. Pancreas 2011; 40: 233-6.
39. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-6.
40. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH, Berger F, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009; 137: 1102-13.
41. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, Robson P,. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem 2005; 280: 24731-7.
42. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A,. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003; 113: 643-55.
43. Hoei-Hansen CE, Nielsen JE, Almstrup K, Sonne SB, Graem N, Skakkebaek NE, Leffers H, Rajpert-De Meyts E,. Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin Cancer Res 2004; 10: 8521-30.
44. Dashwood WM, Carter O, Al-Fageeh M, Li Q, Dashwood RH,. Lysosomal trafficking of beta-catenin induced by the tea polyphenol epigallocatechin-3- gallate. Mutat Res 2005; 591: 161-72.
45. Wong MY, Chiu GN,. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anticancer Drugs 2010; 21: 401-10.